Variations of plasma enzymes in the pony and the dog after carbon tetrachloride administration.

This study compared how liver-related blood tests change in dogs and ponies after a controlled exposure to the liver toxin carbon tetrachloride. It found species-specific responses—ALP rose in dogs while GGT rose in ponies—showing that liver tests must be interpreted differently in each species.

What the researchers did

• Gave adult female dogs and pony mares a nonlethal, standardized dose of carbon tetrachloride (CCl4) at 0.5 ml/kg to induce acute, reversible liver injury.
• Measured several serum/plasma markers before and repeatedly after dosing: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), arginase, gamma-glutamyltransferase (GGT), iditol dehydrogenase (ID; also known as sorbitol dehydrogenase), and total bilirubin.
• Compared the magnitude and timing of changes between dogs and ponies to identify species-specific diagnostic patterns.

Why this matters

• Liver enzymes have different baseline activities, tissue distributions, and inducibility across species; a test that is sensitive in one species may be uninformative in another.
• Understanding species differences prevents misdiagnosis and guides the right choice of tests for clinical evaluation of hepatic disease.
• CCl4 provides a controlled model of toxic liver injury, allowing comparison of biomarker behavior without confounding disease variability.

Key biomarkers and what they indicate

• ALT: marker of hepatocellular leakage; highly informative in dogs, generally less so in adult horses/ponies.
• AST: less liver-specific (also in muscle); rises with hepatocellular injury or myopathy.
• ALP: cholestasis and biliary tract enzyme; also inducible by corticosteroids and bone growth, especially in dogs.
• GGT: biliary epithelial enzyme; highly sensitive for cholestasis in horses/ponies.
• ID (sorbitol dehydrogenase): cytosolic hepatocellular enzyme; short half-life; particularly useful in large animals for detecting acute hepatocellular injury.
• Arginase: hepatocellular enzyme; elevations suggest liver damage but is less commonly used today.
• Total bilirubin: reflects hemolysis, hepatic uptake/conjugation defects, or cholestasis; elevations without jaundice (icterus) can still be clinically relevant.

Main findings in dogs

• GGT: not significantly increased after CCl4 exposure.
• ALP: significantly increased from days 1 to 6 post-dose, indicating a cholestatic or biliary-associated response in this model.
• Total bilirubin: significantly increased later in the course (days 5 to 8), then returned to or fell below baseline; no visible icterus occurred.
• ALT/AST/ID/arginase: measured but not highlighted as discriminatory in the abstract; suggests less striking or species-nonspecific changes relative to ALP in this canine model.

Main findings in ponies

• GGT: significantly increased throughout the entire observation period, consistent with high sensitivity of equine GGT to biliary injury or cholestasis.
• ALP: showed only small, transient (yet statistically significant) increases, indicating ALP is less responsive in ponies than in dogs for this injury type.
• Total bilirubin: significantly increased earlier (days 1 to 4) than in dogs, then normalized or dipped below baseline; no icterus observed.
• AST/ID/ALP when compared across species: described as unremarkable for differentiating pony versus dog, reinforcing that GGT (pony) and ALP (dog) provided the clearest species-specific signals.

Between-species comparison and interpretation

• The most pronounced species differences were:
  • Ponies: robust, sustained GGT increase; modest ALP response.
  • Dogs: pronounced ALP increase; minimal GGT response.
• Total bilirubin rose in both species but with different timing—earlier in ponies and later in dogs—suggesting species-specific kinetics of cholestasis or bilirubin handling after toxic injury.
• AST and ID did not provide strong species separation in this model, despite their roles as hepatocellular injury markers.
• Physiologic context:
  • Equids typically show GGT as a sensitive indicator of biliary disease; ALP has lower diagnostic yield compared with canids.
  • Canine ALP is readily induced and often rises with cholestasis or enzyme induction, making it a sensitive marker in dogs.
  • CCl4 primarily causes centrilobular hepatocellular injury; secondary cholestatic patterns can differ by species due to enzyme expression and induction profiles.

Clinical implications

• Do not generalize liver enzyme interpretation across species:
  • Dogs: prioritize ALP (and often ALT, though not emphasized here) when screening for toxic or cholestatic liver injury; GGT may add less.
  • Ponies/horses: prioritize GGT (and ID/SDH) for early detection of hepatobiliary injury; ALP alone may under-detect disease.
• Use bilirubin trends and timing alongside enzymes; early rises in ponies versus delayed rises in dogs may refine time course assessment.
• Absence of icterus does not exclude clinically meaningful biochemical cholestasis or hepatocellular injury.

Limitations and caveats

• Sample size and exact sampling schedule are not provided in the abstract, limiting precision of effect estimates.
• Only adult females and a single toxin/dose were studied; findings may not generalize to males, juveniles, other toxins, or chronic disease.
• No histopathology is mentioned; correlating enzyme changes to lesion severity or distribution would strengthen inferences.
• Some assays (e.g., ID/arginase) and nomenclature are older; contemporary labs may use SDH (for ID) and have different reference intervals and analytic sensitivities.

How to apply the findings in practice

• For suspected hepatic disease in dogs: include ALP (± ALT, AST, bilirubin) early; interpret GGT cautiously as it may be less responsive.
• For suspected hepatic disease in ponies/horses: include GGT and SDH/ID early; view ALP rises as supportive but not essential.
• Track serial measurements to detect peak timing and resolution, recognizing species-specific kinetics in bilirubin and enzyme responses.

Future research directions

• Define time-resolved enzyme kinetics with larger cohorts and standardized sampling to map peak and half-life by species.
• Integrate histopathology and imaging to link enzyme patterns to lesion types (hepatocellular vs cholestatic vs mixed).
• Evaluate other common hepatotoxins and inflammatory liver diseases to test generalizability of species-specific patterns.
• Compare modern assays (e.g., SDH activity, GLDH) and reference intervals to update diagnostic algorithms for equids and canids.